BioPhorum response to British Pharmacopoeia ATMP working party draft Part 1 guidance; ‘Characterisation of the Particle Population in AAV Products’.
Viewing related articles
AAV Bioreactor scale-up bench-marking survey
Dec 2022 | Benchmarking, Cell & Gene Therapy, Commercialization, Deliverable, Deliverables Report
A BioPhorum member only survey to help gain further insight around how the industry is approaching scaling the production of AAV in suspension HEK- 293 cells from lab to commercial scale.